🚀 VC round data is live in beta, check it out!
IBA Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for IBA Group and similar public comparables like 2seventy bio, Polynovo, Kamada, Myriad Genetics and more.
IBA Group Overview
About IBA Group
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World.
Founded
1986
HQ
Employees
2.1K
Website
Financials (LTM)
EV
$453M
IBA Group Financials
IBA Group reported last 12-month revenue of $716M and EBITDA of $50M.
In the same LTM period, IBA Group generated $50M in EBITDA and $17M in net income.
Revenue (LTM)
IBA Group P&L
In the most recent fiscal year, IBA Group reported revenue of $586M and EBITDA of $34M.
IBA Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $716M | XXX | $586M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $195M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $50M | XXX | $34M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $17M | XXX | $11M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
IBA Group Stock Performance
IBA Group has current market cap of $492M, and enterprise value of $453M.
Market Cap Evolution
IBA Group's stock price is $16.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $453M | $492M | 0.0% | XXX | XXX | XXX | $0.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIBA Group Valuation Multiples
IBA Group trades at 0.6x EV/Revenue multiple, and 9.1x EV/EBITDA.
EV / Revenue (LTM)
IBA Group Financial Valuation Multiples
As of April 19, 2026, IBA Group has market cap of $492M and EV of $453M.
Equity research analysts estimate IBA Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IBA Group has a P/E ratio of 28.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $492M | XXX | $492M | XXX | XXX | XXX |
| EV (current) | $453M | XXX | $453M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBIT | 13.2x | XXX | 38.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.3x | XXX | XXX | XXX |
| P/E | 28.7x | XXX | 45.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (21.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IBA Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IBA Group Margins & Growth Rates
IBA Group's revenue in the last 12 month grew by 2%.
IBA Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
IBA Group's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IBA Group's rule of X is 14% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
IBA Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
IBA Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| IBA Group | XXX | XXX | XXX | XXX | XXX | XXX |
| 2seventy bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Polynovo | XXX | XXX | XXX | XXX | XXX | XXX |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IBA Group M&A Activity
IBA Group acquired XXX companies to date.
Last acquisition by IBA Group was on XXXXXXXX, XXXXX. IBA Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IBA Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIBA Group Investment Activity
IBA Group invested in XXX companies to date.
IBA Group made its latest investment on XXXXXXXX, XXXXX. IBA Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IBA Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IBA Group
| When was IBA Group founded? | IBA Group was founded in 1986. |
| Where is IBA Group headquartered? | IBA Group is headquartered in Belgium. |
| How many employees does IBA Group have? | As of today, IBA Group has over 2K employees. |
| Who is the CEO of IBA Group? | IBA Group's CEO is Olivier Legrain. |
| Is IBA Group publicly listed? | Yes, IBA Group is a public company listed on Euronext Brussels. |
| What is the stock symbol of IBA Group? | IBA Group trades under IBAB ticker. |
| When did IBA Group go public? | IBA Group went public in 1998. |
| Who are competitors of IBA Group? | IBA Group main competitors are 2seventy bio, Polynovo, Kamada, Myriad Genetics. |
| What is the current market cap of IBA Group? | IBA Group's current market cap is $492M. |
| What is the current revenue of IBA Group? | IBA Group's last 12 months revenue is $716M. |
| What is the current revenue growth of IBA Group? | IBA Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of IBA Group? | Current revenue multiple of IBA Group is 0.6x. |
| Is IBA Group profitable? | Yes, IBA Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IBA Group? | IBA Group's last 12 months EBITDA is $50M. |
| What is IBA Group's EBITDA margin? | IBA Group's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of IBA Group? | Current EBITDA multiple of IBA Group is 9.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.